Troendle August J.

CEO Troendle sells 28,876 shares ($17.1M) across two days at $592.70 blended average, near 52-week high.

August J. Troendle, CEO of Medpace Holdings, executed 2 separate sales totaling 28,876 shares for $17,114,846.56 on 2025-12-01 and 2025-12-02 at blended average price $592.70, reducing his holdings from 675,728 to 646,852 shares (-4.3%). The transaction occurred near the 52-week high of $618.49, with current price at $576.49 showing a -6.8% drawdown. Notably, Troendle has executed 5 consecutive sales at this ticker within a 7-day window (2025-11-21 through 2025-12-02), representing sustained sequential liquidation. While his cross-ticker track record shows 62.50% well-timed sell rate at 90 days with +8.4% average 90-day return, those gains suggest his prior sells were historically early exits before rallies—a pattern that currently conflicts with the stock's -3.0% 30-day decline since these recent transactions.

MEDP CEO Troendle sells 56,482 shares for $34,074,469.74 in 2 transactions, 11/26–11/28

CEO August J. Troendle executed 2 separate sales totaling 56,482 shares for $34,074,469.74 on November 26 and 28, 2025, reducing his holdings by 7.7% to 675,728 shares. The blended average sale price of $603.28 sits 2.6% above the current price of $587.98 and near the 52-week high of $618.49, positioning this as a high-priced exit. At Medpace, Troendle has executed 5 straight sells over 6 days (November 20–December 1), marking a sustained pattern of share reduction at elevated valuations. His cross-ticker track record shows a 66.67% well-timed rate on 20 prior sells with positive average returns, but this does not predict accuracy at this specific ticker: the company trades at a rich P/E of 38.26 despite solid 11.8% annual revenue growth and healthy net income of $111,135,000.00. The sustained concentrated selling in recent days warrants tracking whether this reflects conviction to exit at peak prices or liquidity-driven activity.

MEDP CEO Troendle sells 101,417 shares for $61,967,338.34 over two days near 52-week high

CEO August J. Troendle executed two separate sales totaling 101,417 shares for $61,967,338.34 on November 24–25, 2025, at prices of $607.78 and $615.52, reducing his holdings from 833,627 to 732,210 shares (a -12.2% reduction). The sales occurred within 1.9% of the 52-week high of $618.49, reflecting execution near peak valuation. His cross-ticker track record shows 20 prior sells with an 88.89% well-timed rate and an average 90-day return of -0.2%, indicating a pattern of selling before downturns; however, his five prior MEDP sales all occurred within the preceding week (November 18–26) with no measurable 90-day outcomes yet. Medpace's fundamentals remain solid with $659.9M quarterly revenue, +11.8% annual growth, and 39.47 P/E, though the cumulative effect of repeated insider selling concentrated near the 52-week high merits monitoring for any signal of executive reassessment of near-term valuation.

CEO Troendle sells 28,688 shares for $17,031,557.14 (blended avg $593.68) across 2 sales on Nov 20–21; stock now at $618.49 (+0.0% from 52-week high).

Medpace CEO August J. Troendle executed 2 separate sales totaling 28,688 shares for $17,031,557.14 at blended average price $593.68 on November 20–21, 2025, reducing his stake from 862,315 shares to 833,627 shares (-3.3%). The sales occurred near the stock's 52-week high of $618.49, with the current price at +0.0% from that peak and +31.8% over 90 days. Across his cross-ticker open-market history, Troendle's prior 20 sells averaged a poorly-timed 90-day return of +2.2% (showing the stock typically rose after his sales), though his 90-day well-timed rate stands at 90.91%, indicating his recent sales have largely preceded declines. At Medpace specifically, five prior sales in quick succession (Nov 14–24) lack measurable outcomes as they are too recent. The company's fundamentals remain robust with annual revenue growth of +11.8%, net income of $111,135,000.00, and a market cap of $17,421,764,243.27, though the P/E of 40.24 reflects a premium valuation. The confluence of substantial share liquidation near all-time highs by the CEO, combined with his strong recent timing track record across other holdings, merits investor attention to near-term price action.

CEO Troendle sold 31,053 shares in 2 transactions (Nov 18-19) for $18,376,704.78 at $591.79 avg, retaining 862,315 shares

CEO August J. Troendle executed 2 separate sales totaling 31,053 shares for $18,376,704.78 between November 18–19, 2025, at a blended average price of $591.79, reducing his holdings by 3.5% to 862,315 shares. The timing is notable: these transactions occurred as the stock rallied +7.4% over 30 days and +26.4% over 90 days, approaching its 52-week high of $605.20 (current price $586.16 is -3.2% from that peak). Across his cross-ticker track record, Troendle has demonstrated a 92.31% well-timed sell rate over the long term, suggesting experienced execution; however, his 5 most recent MEDP trades (all within days of this filing) have outcomes not yet measurable at 30 or 90 days. The strong recent price momentum and elevated valuation (P/E 38.14) provide context for the sale, though fundamentals remain solid with annual revenue growth of +11.8%.

CEO Troendle sold 20,794 shares (20.8K) for $12,352,076.22 ($12.4M) at MEDP on Nov 14–17; stock near 52-week high at $590.18.

Troendle executed two separate sales totaling 20,794 shares for $12,352,076.22 at prices ($595.26 and $591.00) near the current market level of $590.18, which sits just 2.5% below the 52-week high of $605.20. His post-transaction holdings remain substantial at 893,368 shares, representing a net reduction of 2.3% from his prior stake. Across his cross-ticker open-market history, his 20 prior sells have shown a 93.33% well-timed rate at the 90-day mark, but his same-ticker history at MEDP shows 0 of 0 prior sells were well-timed at 90 days—a limited track record at this specific ticker. The company reports strong fundamentals with revenue of $659,903,000.00 (latest quarter), net income of $111,135,000.00, and annual growth of +11.8%, trading at a P/E of 38.40 on a $16,624,321,850.14 market cap.

Medpace CEO Troendle sells 10,440 shares for $6.3M across two days; stock near 52-week high

CEO August J. Troendle executed 2 separate sales totaling 10,440 shares for $6,288,183.12 across November 12–13 at prices of $603.23 and $601.37, representing a 1.1% reduction from his prior 924.6K share holdings. The sale occurred as Medp's stock trades at $590.09, approximately 2.5% below its 52-week high of $605.20 and following a robust 30-day gain of 14.7% and 90-day return of 28.9%. Reviewing Troendle's prior trades at Medpace (5 trades total), only 1 of 2 measured outcomes at the 90-day mark showed negative post-sale returns, limiting conclusive evidence about his timing accuracy at this ticker. The company operates at a premium valuation (P/E 38.39) with solid near-term fundamentals: $659.9M quarterly revenue, $111.1M net income, and 11.8% annual revenue growth.

Medpace CEO Troendle sells 37.4K shares for $17.8M as stock hits 52-week high; 90-day timing historically strong.

CEO August J. Troendle executed 2 separate sales totaling 37,393 shares for $17,794,383.07, reducing his stake from 961,995 shares to 924,602 shares (-3.9%) at an blended average price of $475.87. The transactions occurred on 2025-08-29 (36,196 shares at $475.90) and 2025-09-02 (1,197 shares at $475.11), with the stock now trading at $481.23 after a 52-week high of $481.23 (current price at range ceiling). His cross-ticker track record across 20 prior open-market sales shows a 100.00% well-timed rate at the 90-day mark, though at MEDP specifically, 4 of 4 prior measurable sales have delivered negative 90-day returns. The company's 11.8% annual revenue growth and $603.3M latest quarterly revenue provide a solid operating context, but the CEO's consistent sell pattern at or near multiyear peaks warrants monitoring of subsequent price action relative to his historical timing accuracy.

CEO Troendle sells 48,487 shares of MEDP for $21.9M; prior 5 sales all well-timed at 90-day mark with average -3.5% return

CEO August J. Troendle sold 48,487 shares at $451.69 on 2025-07-28, generating $21,901,093.03 in proceeds and reducing his holdings by 4.8% to 962.6K shares. His track record at MEDP is notably predictive: all 5 prior sales at this ticker achieved negative 90-day returns (ranging from -2.2% to -5.2%), indicating he has consistently sold ahead of near-term declines. The current stock price of $447.92 is 6.2% below the 52-week high of $477.73, and the stock has surged 44.2% in the past 30 days after a 45.2% 90-day rally. This sale during a period of strong momentum, combined with a 100% success rate on prior same-ticker sales at identifying inflection points, suggests the CEO recognizes current valuations as an exit opportunity before a potential pullback.